Objectives This study aimed to evaluate the feasibility and mid-term outcomes of in situ aortic reconstruction using xenopericardial roll grafts for thoracic and thoracoabdominal native aortic and prosthetic graft infection.Methods This retrospective single-centre study included consecutive patients who underwent xenopericardial roll graft replacement, including branched graft reconstruction and/or tissue filling, between 2010 and 2024. A multidisciplinary treatment strategy was adopted.Results This study included 21 patients who underwent 22 procedures (median age, 67 years; interquartile range, 63.75-73.75). On a procedure basis, the indications were infectious aortic aneurysm in 4 procedures and prosthetic graft infection in 18 procedures. Replacement sites included the ascending aorta (n = 4), aortic arch (n = 11), descending aorta (n = 6), and thoracoabdominal aorta (n = 1). Tissue filling was performed in 12 procedures. The 30-day and operative mortality rates were 13.6% (3/22) and 18.2% (4/22), respectively. After excluding the three procedures with 30-day mortality, 19 procedures were included in the Kaplan-Meier analyses. Aorta-related mortality occurred in 10.5% (2/19), both due to fungal reinfection. The median follow-up was 53.6 months (IQR, 20-80.5; maximum, 132 months). The estimated survival rates at 1, 3, 5, and 7 years were 94%+/- 6%, 76%+/- 11%, 70%+/- 11%, and 56%+/- 15%, respectively. Xenopericardial roll graft-related structural complications included suture-line pseudoaneurysm (n = 2), suture-line rupture (n = 1), branch kinking (n = 1), xenopericardial roll graft body pseudoaneurysm (n = 1), and proximal anastomotic pseudoaneurysm (n = 1). No thromboembolism or graft calcification was observed.Conclusions Xenopericardial roll graft replacement was technically feasible as part of a multidisciplinary staged strategy in selected patients with thoracic and thoracoabdominal native aortic or prosthetic graft infection. However, fungal reinfection and xenopericardial roll graft-related structural complications remain important concerns, and careful long-term surveillance is required.Clinical Trial Registration Not applicable. This study is a retrospective observational study.
Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) accounts for 2‒7
To describe surgical outcomes, technical considerations, and feasibility of redo minimally invasive mitral valve surgery using initial cases as a reference cohort. A single-center, retrospective review of minimally invasive mitral valve surgery performed between January 2014 and January 2024 was conducted. Perioperative data, mid-term survival, and cardiac-related events were assessed in both initial and redo groups. A total of 647 patients were included: 30 in the redo group and 617 in the initial group. The redo group had higher European System for Cardiac Operative Risk Evaluation II scores (p < 0.001). In the redo group, 26 (86.7
To determine whether dual antiplatelet therapy improves survival and major ischemic outcomes, and whether it increases major bleeding, compared with aspirin alone after coronary artery bypass grafting. PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception to March 2026 for randomized controlled trials comparing aspirin plus a platelet adenosine diphosphate receptor inhibitor with aspirin alone after coronary artery bypass grafting. The primary outcome was all-cause mortality. Secondary outcomes were major adverse cardiovascular events, myocardial infarction, stroke, and major bleeding. Risk ratios were pooled with random-effects models. Nine randomized trials involving 3,516 patients were included. Eight trials involving 3,496 patients reported all-cause mortality. Dual antiplatelet therapy was not associated with a significant reduction in all-cause mortality (risk ratio 0.77, 95
